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Abstract: The DKK3 gene encodes a secreted protein, Dkk-3, that inhibits prostate tumor growth and
metastasis. DKK3 is downregulated by promoter methylation in many types of cancer, including
prostate cancer. Gene silencing studies have shown that Dkk-3 maintains normal prostate epithelial
cell homeostasis by limiting TGF-β/Smad signaling. While ectopic expression of Dkk-3 leads to
prostate cancer cell apoptosis, it is unclear if Dkk-3 has a physiological role in cancer cells. Here,
we show that treatment of PC3 prostate cancer cells with the DNA methyltransferase (DNMT)
inhibitor decitabine demethylates the DKK3 promoter, induces DKK3 expression, and inhibits
TGF-β/Smad-dependent transcriptional activity. Direct induction of DKK3 expression using
CRISPR-dCas9-VPR also inhibited TGF-β/Smad-dependent transcription and attenuated PC3 cell
migration and proliferation. These effects were not observed in C4-2B cells, which do not respond to
TGF-β. TGF-β signals can regulate gene expression directly via SMAD proteins and indirectly by
increasing DNMT expression, leading to promoter methylation. Analysis of genes downregulated by
promoter methylation and predicted to be regulated by TGF-β found that DKK3 induction increased
expression of PTGS2, which encodes cyclooxygenase-2. Together, these observations provide support
for using CRISPR-mediated induction of DKK3 as a potential therapeutic approach for prostate
cancer and highlight complexities in Dkk-3 regulation of TGF-β signaling.
Keywords: prostate cancer; gene promoter methylation; TGF-β signaling; Dickkopf-3; PTGS2
1. Introduction
Prostate cancer (PCa) is the most commonly diagnosed cancer and the second cause of
cancer-related deaths among men in the U.S. [1]. Survival rates in the last five years have improved
as a result of improved earlier diagnosis and the implementation of prostate specific antigen (PSA)
test screening. First line treatment includes androgen receptor (AR)-directed therapies, since most
tumors express AR and depend on its signaling. However, many patient tumors become resistant
after hormone-therapy and relapse within 24 months, developing castration-resistant PCa (CRPC) [2],
highlighting the need for novel therapies and treatments targeting alternative signaling pathways
involved in PCa progression. Recent studies have demonstrated that epigenetic alterations, particularly
changes in gene promoter methylation, are frequent during PCa tumorigenesis [3]. Cancer genomics
studies have identified recurrently mutated genes and mutation hotspots in a number of cancer
types. However, such studies in prostate adenocarcinomas have identified no genes recurrently
mutated in more than a seventh of cases [4]. The biological, and hence clinical behavior, of prostate
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adenocarcinomas may therefore be determined by variations in the levels of expression of a range
of genes, regulated by epigenetic mechanisms. Epigenetic aberrations play an important role in the
pathogenesis of the majority of cancers, and one of the most widespread and powerful mechanisms
is gene silencing through DNA methylation [5]. DNA methylation is a chemical process defined
as the covalent addition of a methyl group to the 5′ carbon of a cytosine nucleotide, leading to the
formation of 5-methylcytosine within the so-called CpG dinucleotides [6]. CpG dinucleotides are
usually located in clusters named CpG islands, commonly found in the promoter regions of genes, and
their hypermethylation results in the repression of gene transcription by further direct and indirect
mechanisms [5,7,8]. The detection of DNA methylation changes in cancer genomes can highlight
genes that may provide evidence of deregulated signaling networks and pathways, as well as potential
candidates for biomarker development. The process of DNA methylation is tightly regulated by DNA
methyltransferases (DNMTs) and DNA demethylases, respectively [9]. The DNMT family includes
DNMT1, DNMT3 (DNMT3A, DNMT3B), and DNMT3L [8]. DNMT3A and DNMT3B are de novo
methyltransferases that function independently of replication and initiate methylation at CpG sites
on unmethylated and/or hemi-methylated DNA [10]. On the other hand, DNMT1 is a maintenance
methyltransferase that acts during replication and has a preference for hemi-methylated DNA [11].
Demethylation is carried out by the ten-eleven translocation (TET) family of DNA hydroxylases,
which regulate demethylation by oxidizing 5-methylcytosine to 5-hydroxymethylcytosine and further
derivatives and are deregulated in many cancer, including prostate cancer [12].
To date, over 860 genes have been described as hypermethylated in PCa [3]. Of note, the
Dickkopf-related protein 3 (DKK3) gene, also known as ‘reduced expression in immortalized cells’
(REIC), is remarkably silenced by promoter methylation in many types of cancer, including PCa [13–15],
particularly in high Gleason grade tumors [16]. The DKK3 gene product, Dickkopf-3 (Dkk-3), plays a
role in prostate gland architecture [17] and displays potent tumor suppressor activity [18]. Ectopic
expression of DKK3 in PCa cells leads to apoptosis [13,19] and inhibits proliferation, migration [15,20],
and metastasis [19]. Moreover, injection of a DKK3-expressing adenovirus into the tumors of a patient
with incurable PCa reduced metastatic tumor growth [21], and an early stage clinical trial found that
intra-prostatic injection of DKK3 adenovirus significantly improved survival of patients with high-risk
localized PCa [22]. Thus, it may be possible to develop new therapies that re-activate Dkk-3 expression
or that activate the Dkk-3 signal in cancer cells.
Dkk-3 is a member of a family of secreted glycoproteins first identified as inhibitors of
Wnt/β-catenin signaling, through their ability to bind to LRP5/6 Wnt co-receptors [23]. Unlike the
other family members, however, Dkk-3 does not associate with LRP5/6 and its effect on Wnt/β-catenin
activity remains controversial [21]. We and others have found that Dkk-3 regulates the response to
transforming growth factor-β (TGF-β) in prostate epithelial, stromal, and PCa cells [20,24,25]. TGF-β
signaling can have pro- and anti-tumorigenic effects, depending on cellular context and stage of
progression [26]. Binding of TGF-β to its receptors leads to phosphorylation of Smad2/3, resulting
in transcriptional regulation of target genes. In early-stage cancers, this leads to cell cycle arrest
and/or apoptosis, but is pro-tumorigenic in advanced cancers, promoting tumor cell motility, invasion,
and metastasis [27]. The molecular drivers for the switch from anti- to pro-tumorigenic effects are
attractive targets for cancer drug development and are under intense research [28–31]. In addition,
TGF-β increases DNMT expression in PCa [32], providing an indirect route to regulation of gene
expression. Indeed, many genes found to be hypermethylated in PCa are linked to TGF-β signaling [33].
A number of DNA demethylating drugs have been approved by the FDA (Food and Drug
Administration), for example, azacitidine and decitabine [34]. Despite positive responses in acute
myeloid leukemia patients, acquired resistance is common, and these drugs are less effective in
solid tumors. Improved versions are being developed and are in clinical trials for PCa (reviewed
in [35] [36]), but this class of inhibitors will always have a global impact on the epigenome and
therefore lack specificity for tumor suppressor genes. Thus, alternative methods targeting specific
epigenetic alterations in cancer may be a more effective approach. In this context, the CRISPR-Cas9
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system is attractive, as it can be used to target genes precisely. CRISPR-Cas9 genome editing uses
the endonuclease Cas9 to induce targeted indels and precise sequence changes. A guide RNA
(gRNA) molecule binds to Cas9 and directs it to a complementary target sequence, where the protein
performs a DNA double-stranded break. Several groups have developed modified versions of Cas9
for applications that go beyond genome editing. Bikard et al. engineered dCas9 by mutating the
Cas9 catalytic site [37], and Chavez et al. fused dCas9 to a tripartite transcriptional activation domain
(dCas9-VPR) to induce expression of gRNA target genes [38]. Here, we use dCas9-VPR and gRNAs
targeting the DKK3 gene promoter to examine the consequences of re-activating endogenous DKK3
expression on PCa cell physiology and on the expression of genes regulated by promoter methylation.
Our results demonstrate that CRISPR-dCas9-VPR induction of Dkk-3 is sufficient to inhibit the response
to TGF-β and alter the expression of PTGS2, a TGF-β regulated gene that is methylated in PCa.
2. Results
2.1. Decitabine Treatment of PC3 Cells Increases DKK3 Expression and Inhibits TGF-β-Dependent Gene
Reporter Activity
In order to confirm that DKK3 mRNA expression is repressed by promoter methylation, PC3
cells were analyzed using Combined Bisulfite Restriction Analysis (CoBRA) to determine the extent of
DKK3 gene methylation at the promoter CpG island. This confirmed a high level of methylation that
was reduced by treatment of cells with decitabine (Figure 1A), consistent with previous studies [39].
Moreover, analysis of DKK3 gene expression by q-RT-PCR indicated that decitabine treatment increased
DKK3 mRNA levels, both in PC3 cells, as previously reported [39], and in C4-2B cells (Figure 1B).
Given the links between Dkk-3 and TGF-β-signaling [20,24,40], gene reporter assays were carried
out to determine the effects of decitabine on TGF-β-dependent transcription using pGL3-CAGA12,
which encodes the luciferase gene fused to 12 repeats of a Smad-binding site, and renilla, to control for
transfection efficiency. Decitabine reduced TGF-β-dependent gene reporter activity in PC3 cells but
not in C4-2B cells (Figure 1C), consistent with Dkk-3 inhibition of TGF-β signaling in PC3 cells and not
in C4-2B cells, which do not express TGFBR2 [41].
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Figure 1. Decitabine treatment of PC3 cells increases DK 3 expression and inhibits TGF-β-dependent
gene reporter activity. (A) Combined bisulfite r striction analysi ( ) of D K3 g ne promoter
methylation in PC3 cells after tr a ment with decitabine (2 µM, 3 el shows undigested (U) and
BstUI-digested (D) PCR products, * prom ter de-methylation. (B) - - analy is of DKK3 mRNA
levels in untreated and 5-aza-2′deoxycytidine (5-aza-dC)-treated PC3 and C4-2B cells; * p < 0.05, 2-tailed
Student’s t-test versus untreated. (C) TGF-β-dependent gene reporter activity (luciferase/renilla),
relative to control, in PC3 and C4-2B cells transfected with CAGA12-luciferase and renilla and either
untreated (control) or treated with decitabine (Aza) and/or TGF-β for 24 h. Data are shown as
means ± SEM (n = 3). * p < 0.05, ANOVA and two-tailed Student’s t-test.
2.2. CRISPR-Mediated Activation of the DKK3 Promoter Increases DKK3 mRNA and Dkk-3 Protein Levels
Decitabine is likely to have global effec s on gene expr ssion, so its effect o TGF-β-dependent
gene reporter activity could be u related to DKK3 mRNA expression. T erefore, in rder to activate
endogenous DKK3 expression specifically, we used CRISPR to target the transcriptional activator
dCas9-VPR to the DKK3 gene promoter. Five guide RNAs (gRNAs) targeting different sites of the
DKK3 promoter were designed (Figure 2A). Plasmids expressing these gRNAs, individually or in
combination were co-transfected with dCas9-VPR plasmid and DKK3 mRNA expression was measured
by q-RT-PCR after 48 h. The results showed a remarkable increase of DKK3 mRNA levels, the extent
of which depended on the gRNA used and the cell line transfected. In PC3 cells, g A-1, -2 and
-4 significantly increased DKK3 gene expression, as did the combination of all five gRNAs (gAll)
(Figure 2B). Th same gRNAs incr ased D K3 expr ssion n C4-2B cells, with gRNA-4 being the
most effective, achieving a >400-fold increase (Figure 2C). Next, western blotting analysis was used to
determine if the increases in DKK3 mRNA expression were sufficient to lead to detectable levels of
Dkk-3 protein. Analysis of cell extracts and cell-conditioned media (CM) five days after transfection
revealed that transfection of dCas9-VPR with the combination of all five gRNAs led to detectable levels
of Dkk-3 protein in cell extracts and in cell CM, both in PC3 (Figure 2D) and C4-2B (Figure 2E) cells.
ELISA analysis of cell CM at 72 h found that the amounts of Dkk-3 in CM from PC3 cells transfected
with control gRNA and DKK3 gRNAs were 0.027 ± 0.033 and 0.105 ± 0.084 ng/mL (mean and SD,
n = 3), respectively. In C4-2B c ll CM, this was 0.035 and 1.3 ng/ml, respectively. These results indicate
that CRISPR/dCas9-VPR induction of DKK3 mRNA expression leads to low but measurable levels of
secretion of Dkk-3 protein. In order to determine if DKK3 expression could be induced by targeted
demethylation of the DKK3 promoter, we used an expression vector encoding dCas9 fused to the
catalytic domain of the demethylase Tet1 (dCas9-Tet1CD) [42]. Expression of DKK3 gRNAs with
dCas9-Tet1CD significantly increased DKK3 mRNA expression in PC3 cells and C4-2B cells, and this
was not observed using an inactive mutant of Tet1 (Figure 2F). However, we were unable to detect
Dkk-3 protein at the time point used in either cell line.
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2.3. CRISPR-Mediated Induction of Dkk-3 Inhibits TGF-β Signaling in PC3 Cells
In order to determine if CRISPR induction of Dkk-3 inhibits TGF-β-dependent signaling, gene
reporter assays were carried out using cells transfected with luciferase reporters and dCas9-VPR and
either control or DKK3 gRNAs. TGF-β treatment increased CAGA luciferase activity in PC3 cells
transfected with control gRNA, as expected (Figure 3A). This activity was reduced by transfection
of DKK3 gRNAs, indicating that CRISPR-mediated induction of Dkk-3 inhibits TGF-β-dependent
signaling. In contrast, induction of Dkk-3 in C4-2B cells had no effect on CAGA luciferase activity
(Figure 3B), consistent with the negligible effects of TGF-β in these cells, which do not express TGF-β
receptors [41].
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if CRISPR-mediated induction of DKK3 affects prostate cancer cell number, cells were transfected 
with dCas9-VPR and control or DKK3 gRNAs and cultured for two days and five days, after which 
cells were fixed and stained using crystal violet to provide a measure of cell number. Compared to 
control gRNA, transfection of dCas9-VPR with DKK3 gRNAs did not significantly affect cell number 
at two days (Figure 4A). After five days, however, there was a notable and significant reduction in 
cell number. On the other hand, there was no effect on C4-2B cell number at either time point (Figure 
4B). These results indicate that CRISPR activation of DKK3 expression has a limited and delayed 
effect on cell number, in contrast to what has been observed using ectopically expressed DKK3. 
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DKK3 (All-gRNAs) gRNAs after two or five s. lues shown represent the average fold change,
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2.5. CRISPR-Mediated Induction of Dkk-3 Reduces PC3 Cell Migration
Given the effect of CRISPR induction of DKK3 on TGF-β-dependent transcriptional activity, we
wished to determine if it l o ha an impact on TGF-β-dependent prostate cancer cell migration. To this
end, cells were t ansfected, cultured for one or four days and then plated in inserts in serum-free
media with or without TGF-β, and with medium containing 10% FCS in the lower chamber. After
24 h, migrated cells were stained and counted. CRISPR induction of DKK3 did not significantly affect
the migration of PC3 (Figure 5A) or C4-2B (Figure 5B) cells when they were cultured for one day
prior to plating for migration assays. However, when transfected cells were cultured for four days
prior to plating, expression of dCas9-VPR and DKK3 gRNAs significantly reduced TGF-β-dependent
migration (Figure 5A). A reduction was also observed both in the absence of exogenous TGF-β,
possibly reflecting inhibition of autocrine TGF-β signaling. In contrast, there was no significant effect
on C4-2B cell migratio (Figure 5B). Equal numbers of viable cells were pl ed i each case, so the
effect on cell migration was ot a r ult of a reduction in cell number. These results indicate that
activation of endogenous DKK3 expression inhibits PC3 but not C4-2B cell migration, in keeping with
its effects on TGF-β signaling in these cell lines.
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transfected for one or four days with dCas9-VPR and either control (gRNA-control) or DKK3 (All
gRNAs) gRNAs were plated in transwell inserts in serum-free medium± 2 ng/mL TGF-β1 and allowed
to migrate for 24 h. (A,B) Graphs show average fold change in cell migration (± TGF-β) for PC3 (A) and
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2.6. Effect of Activation of Endogenous DKK3 on Gene Expression
TGF-β regulates the expression of DNMT1, whose expression predicts disease recurrence [32],
and many genes hypermethylated in PCa are linked to TGF-β signaling [33]. We therefore wished to
determine if DKK3 has an impact on genes that are methylated in PCa and potentially regulated by
TGF-β. To identi y such genes, we re-analyzed data for differential DNA methylation of genes in PCa
and normal (benign) prostate [3], focusing on the 168 genes that were identified as hyp rmeth lated
in at least 3 of the 17 studies examined (Figure S1). Defining probes with β-values > 0.5 and < 0.35
as methylated and un-methylated, respectively, provided a list of 49 genes that were differentially
methylated in benign prostate and PCa (Figure 6A). The differential mRNA expression of these
genes in PCa, compared to in normal prostate was then analyzed using PCa datasets from Oncomine
(https://www.oncomine.org) and cBioPortal for Cancer Genomics (http://www.cbioportal.org) and
the genes were ranked according to their downregulated expression in PCa (Figure S2). Finally,
ToppGene (https://toppgene.cchmc.or /) was used to identify genes with significant links to TGF-β
signaling. Among thes genes, we selected PTSG2, ANXA2, HFE, SLC16A5, and CYP27A1 for further
analysis. In addition, we analyzed DKK3 and other genes potentially regulated by DKK3 [43], by
TGF-β (FZD8 [44]) or by Wnt signaling (NKD1).
Analysis of the methylation status of the promoters of these genes in PC3 cells using Gene
Expression Omnibus (GEO) (ncbi.nlm.nih.gov/geo/) indicated that DKK3, SLC16A5, PTGS2, HFE,
and TGFBI had β-values > 0.5, while CYP27A1, ANXA2, and FZD8 had β-values < 0.35. For the DKK3
promoter (Figure S3) the average β-values were 0.86 and 0.18 in PC3 and RWPE1 cells, respectively
(Figure 6B). Analysis of these genes in patient samples from the TGCA dataset using the MethHC
databas (methhc.mbc.nctu.edu.tw) confirmed significant hypermethylati n of the DKK3, PTGS2,
SLC16A5, HFE, nd CYP27A1 promoters in prostate tumors, compared to normal prostate. ACTG2
and ECM1 were also more highly methylated in tumors than in normal prostate, but from a high basal
level, while TGFBI and ANXA2 were more highly methylated in tumors, but from a low basal level in
normal prostate. NKD1 and FZD8 were only very weakly methylated both in patient tumors and in
normal prostate (Figure 6C).
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In order to determine the extent to which the expression of these genes is regulated by gene
promoter methylation in PCa, q-RT-PCR analysis was carried out to measure mRNA expression in
PC3 cells treated with decitabine. ost of the genes were significantly upregulated after 24 h, with
PTGS2 being the most highly-induced (Figure 7A), while there was no effect on ANXA2 and FZD8,
consistent with their low levels of methylation. e then examined the effects of CRISPR-mediated
induction of DKK3 on the expression of the same genes. Induction of DKK3 resulted in a significant
increase in the expression of PTGS2 and trends for increased expression of SLC16A5 and for reduced
expression of TGFBI and FZD8 (Figure 7B). Finally, we examined the effects of TGF-β on the expression
of some of the genes. As expected, TGFBI was highly-induced by TGF-β treatment of PC3 cells
(Figure 7C). In addition, TGF-β treatment resulted in significant increases in the expression of PTGS2
and SLC16A5 and a trend for increased expression of HFE. CRISPR induction of DKK3 (22-fold) was
similar to its induction by decitabine (19-fold), while there was a trend for increased DKK3 expression
in TGF-β-treated cells (Figure 7D). Comparison of the effects of decitabine, CRISPR-mediated DKK3
activation, and TGF-β suggested that, among the genes examined, the regulation of PTGS2 expression
matched most closely to that of DKK3 (Figure 7E). To determine the clinical relevance of PTGS2
expression, cBioPortal was used to look for correlations with disease recurrence, which found PTGS2
levels altered >1.5-fold in 24% of the 150 sequenced patient tumors from the Taylor et al. MSKCC
dataset [45] (Figure 7F). Importantly, among the recurrent tumors, only reduction in expression was
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observed (10 cases), whereas among the disease-free tumors, PTGS2 was reduced in 11 and increased
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3. Discussion
Epigenetic silencing of the tumor suppressor DKK3 by promoter methylation is a common event in
many solid tumors and is more prevalent in advanced stages of the disease. Advanced PCa continues to
have a poor survival rate due to acquired resistance to the treatments currently available, emphasizing
the need for finding new targets for more effective therapies. When designing strategies to prevent
cancer progression, gene hypermethylation presents the advantage of being readily reversible, in
contrast to permanent alterations in DNA, such as point mutations or gene deletions. Considering the
previous reports describing the tumor suppressive roles of DKK3 [13,15,19,20], its inhibitory effect on
malignant TGF-β signaling [20,24], and its potential in recent clinical trials [21,22], we have focused
on reactivating endogenous DKK3 expression using a CRISPR-based approach. This has advantages
over ectopic expression of DKK3, which can be toxic [46], and over using recombinant Dkk-3, which
has little apparent activity in many contexts [25]. Moreover, by directly targeting the DKK3 genomic
locus, the CRISPR-based approach should result in expression of all variants. This is particularly
important when considering the effects of Dkk-3 isoforms, for example, the intracellular form of Dkk-3,
Dkk-3b [47]. CRISPR activation of DKK3 also provides specificity, unlike demethylating drugs [34]. In
this study, we used dCas9-VPR to induce DKK3 expression to a level that was sufficient to affect PC3
cell number and migration. The VPR transcriptional activation domain proved essential in this context,
since induction of DKK3 mRNA by dCas9-Tet1CD did not lead to increased Dkk-3 protein levels.
However, we anticipate that targeted demethylation can be improved by using lentiviral delivery and
allowing more time for induction to take place. A general limitation of the CRISPR approach is that it
requires a means of delivery, for example using viral vectors (reviewed in [48]). However, a modified
CRISPR/Cas9 system was recently used with success for gene activation in vivo [49], indicating the
emerging importance of this technology in translational applications.
A major goal of this study was to investigate the effect of DKK3 re-expression on TGF-β/Smad
signaling, since overexpression of this pathway is frequently observed in advanced metastatic PCa
patients and is associated with poor survival. Our results indicate a significant inhibition of the
response to TGF-β1 when DKK3 is re-expressed in PC3 cells. This outcome is in agreement with
previous studies reporting links between DKK3 and TGF-β signaling [20,24].
One of the tumor suppressive mechanisms described for DKK3 is its inhibition of cell
proliferation [18]. Our results using PC3 cells are consistent with these previous studies and indicate
that CRISPR activation of DKK3 has a negative effect on cell number. Importantly, although there
was a small reduction in cell proliferation two days after transfection, it was only at the later time
point when this reduction was significant. This highlights an important aspect of the approach used,
in which time is required for induction of endogenous Dkk-3 to reach a level where it has a measurable
physiological effect on cells. In contrast to PC3 cells, DKK3 induction had no effect on C4-2B cell
number at the time points studied. This might imply a link between the effects of Dkk-3 on prostate
cancer cell proliferation and on TGF-β signaling. However, if this is the case, the mechanism remains
unclear, as TGF-β does not affect PC3 cell proliferation [50]. In LNCaP cells, the parental line for C4-2B,
adenoviral expression of DKK3 reduces CD147 levels, concomitant with a reduction in cell growth [51].
However, we did not find significant differences in the expression of the genes encoding CD147 or
its accessory proteins MCT1/4 after CRISPR-mediated induction of DKK3 in PC3 cells [52]. Given
the limited effects of Dkk-3 induction on prostate cancer cell proliferation, it would be interesting to
explore its effects when used in combination with other therapies. In this context, downregulation
of DKK3 gene expression by DNA promoter methylation in non-small cell lung cancer has been
reported to increase resistance to docetaxel [53]. Since docetaxel is the standard chemotherapy drug
used to treat castrate-resistant prostate cancer, it would be interesting to determine the effects of
combining CRISPR-mediated activation of DKK3 with docetaxel and of restoring DKK3 expression in
docetaxel-resistant prostate cancer cells.
In addition to the effect on cell proliferation, we demonstrated that endogenous re-expression of
DKK3 results in the attenuation of cell migration. In these assays, we also observed that the effect of
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DKK3 was only substantial at the later time point. Interestingly, we also detected a significant inhibition
in migration in the absence of exogenous TGF-β, which may reflect inhibition of migration driven by
autocrine TGF-β signals [50]. TGF-β is a well-established promoter of the epithelial-mesenchymal
transition (EMT) in prostate epithelial and prostate cancer cells [54]. This response to TGF-β in
prostate epithelial cells is, in part, mediated by increased methylation of the E-cadherin gene (CDH1)
promoter [55]. Also, as prostate cancer progresses, it can take on a neuroendocrine (NE)-like phenotype.
It is possible, therefore, that induction of DKK3 reverses the EMT or NE-like phenotype. However,
preliminary analysis of RNA-Seq data from PC3 cells transiently expressing dCas9-VPR and either
control gRNA and DKK3 gRNA did not find significant differences in the expression levels of
mesenchymal genes (VIM, SNAI1, SNAI2, SNAI3, ZEB1, ZEB2, TWIST1, TWIST2, and CDH2),
epithelial genes (CLD1 and CDH1), or neuroendocrine (NE) genes (ENO2 and CHGA), apart from
ZEB2, which increased slightly (1.27-fold, p = 0.047) [52]. This suggests that Dkk-3 has a different
mechanism of action. Alternatively, the lack of effect on EMT/NE genes may be because PC3 cells
express very high levels of EMT and NE genes that are difficult to reverse. Future studies will need to
address this question in prostate cancer cell lines with stronger epithelial features and that respond to
TGF-β.
Despite strong evidence implicating TGF-β signaling in driving the methylation of several genes
in PCa and the inhibition of TGF-β signaling by DKK3, we only observed significant differences
in the expression of PTGS2. It is important to note that these analyses were performed 48 h after
transfection, and therefore, if DKK3 inhibits TGF-β signaling indirectly, more significant changes in
gene expression may only be detected at later time points. It remains to be determined if PTGS2
upregulation plays a role in the tumor-suppressive effects of DKK3. This may seem unlikely, as PTGS2
encodes cyclooxygenase-2 (COX-2), which is upregulated in PCa [56]. However, reduced expression of
PTGS2 mRNA by promoter hypermethylation has been reported to be an indicator of poor prognosis
in PCa [57] and the COX-2 inhibitor celecoxib does not improve PCa patient survival [58]. Moreover,
our analysis also found a correlation between low PTGS2 expression and tumor recurrence (Figure 7F).
TGFBI, in contrast, is strongly induced by TGF-β and can promote prostate tumor growth
and metastasis [59]. DKK3 silencing increases TGFBI levels in prostate epithelial cells [43], so we
anticipated that DKK3 re-expression might inhibit TGFBI expression in PC3 cells, and a trend for
inhibition was observed.
We were intrigued to note that CRISPR activation of DKK3, which inhibited TGF-β-dependent
gene reporter activity (Figure 3A), had opposite effects on PTGS2 and FZD8 expression, despite both
PTGS2 and FZD8 being induced by TGF-β. Since PTGS2 but not FZD8 was upregulated by decitabine
(Figure 7A), we considered the possibility that differences in promoter methylation might account for
their differential responses to DKK3. The ability of decitabine to function as an indirect inhibitor of
TGF-β signaling has been reported in other contexts. For example, decitabine reverses TGF-β-induced
EMT in gastric cancer cells [60] and in PC9 non-small cell lung cancer cells [61] by reducing aberrant
TGF-β-induced hypermethylation of the miR-200 gene promoter. At low doses, decitabine induces the
proteasomal degradation of DNMT1, reducing proliferation and inducing differentiation [62]. Thus,
decitabine might be described as an indirect inhibitor of TGF-β signaling.
TGF-β has been reported to increase DNMT gene expression in prostate cancer [32], which
could lead to induction of genes via promoter demethylation. Analysis of DNMT family gene
expression in PC3 cells confirmed that TGF-β treatment increased expression of DNMT1, DNMT3A,
and DNMT3B (Figure S4A). Interestingly, CRISPR induction of DKK3 resulted in a small but significant
reduction in the expression of DNMT1 and trends for increased expression of DNMT3A and DNMT3B
(Figure S4B). DNMT1 was the most abundant of the DNMTs (average Ct values for DNMT1, DNMT3A,
and DNMT3B were approximately 24, 28, and 28, respectively). Thus, by reducing DNMT1 expression,
DKK3 may facilitate promoter demethylation, resulting in increased expression of PTGS2, whose
expression was found to be most sensitive to decitabine (Figure 7A). In contrast, DKK3 inhibited FZD8
expression, an unmethylated TGF-β-regulated gene. A limitation of this study is the selection of a
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small number of genes for analysis. Future studies using whole-genome approaches to measure the
effects of DKK3 on gene promoter methylation and transcription should help test this hypothesis and
take us closer to determining the mechanism of action of DKK3.
4. Materials and Methods
4.1. Cell Lines and Cell Culture
The PC3 human prostatic small cell carcinoma cell line [63] and the C4-2B cell line, which
originated from the human adenocarcinoma LNCaP cell line after selection for metastasis to bone in
mouse xenografts [64], were used in this study. Both cell lines were kindly provided by Charlotte
Bevan (Imperial College London, London, UK). Cells were maintained in complete medium (RPMI
1640 with GlutaMAXTM (Sigma-Aldrich Company Ltd., Gillingham, UK) supplemented with 10%
Fetal Calf Serum (FCS) and 100 units/mL of penicillin and streptomycin (P/S)). Cells were cultured at
37 ◦C and 5% CO2.
4.2. Plasmid Vectors and gRNA Design
The sequences of the DKK3 gene promoter region containing the CpG islands were extracted
using the UCSC genome browser. Potential gRNA sequences, predicted using sgRNA Designer
(www.portals.broadinistitute.org), were selected to bind between 1 and 1000 bp upstream of the
transcriptional start site (TSS). Five gRNAs targeting different DKK3 sites and a scrambled gRNA
(gRNA-control) were cloned into pRP[gRNA]-Puro-U6 (Cyagen Biosciences Inc., Santa Clara, CA,
USA). dCas9-VPR (#63798), dCas9-Tet1CD (#84475), and dCas9TetCD_IM (#84479) were from Addgene
LGC Standards (Teddington, UK). Sequences for gRNAs are listed in Table S1.
4.3. Transient Transfection
Transfections were performed using the Lipofectamine® LTX and Plus Reagent (Life Technologies
Limited, Paisley, UK) according to the manufacturer’s protocol. Cells were transfected in 6-well plates
seeded with 5 × 105 cells per well. For experiments where gRNAs were transfected together, the
amount of each gRNA was scaled down to equalize the total amount of gRNA used for each condition
and the dCas9-VPR to gRNA ratio was 3:1.
4.4. RNA Extraction, cDNA Synthesis, and qPCR
RNA was isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA), according to
manufacturer’s instructions. Quantitative real-time PCR (q-RT-PCR) was performed using the SYBR
Green PCR Master Mix (Life Technologies Limited) and a 7900HT Fast Real-Time PCR thermal cycler
(Fisher Scientific UK Ltd., Loughborough, UK), using the amplification parameters: 50 ◦C for 2 min and
95 ◦C for 10 min, followed by 40 cycles at 95 ◦C for 15 s and 60 ◦C for 1 min. Raw count values obtained
with SDS 2.0 (Applied Biosystems, Foster City, CA, USA) were imported into Excel to calculate the
fold changes, normalized to expression of the gene 36B4 in the same sample. Relative quantification
was carried out using the 2-∆∆Ct method. The primer sequences and the concentrations used for PCR
are in Table S2.
4.5. Demethylation Using 5-Aza-2′Deoxycytidine (5-Aza-dC)
PC3 cells were plated in 6-well plates for 24 h and treated with 1 µM 5-Aza-dC for three days, by
which time cells were 80% confluent and then harvested. 5-Aza-dC was prepared fresh in ddH2O and
filter-sterilized (Sigma-Aldrich Company Ltd.).
4.6. Genomic DNA Extraction, Bisulfite Conversion, and Combined Bisulfite Restriction Analysis (CoBRA)
Genomic DNA was extracted from PC3 cells using the DNeasy Blood and Tissue Kit (Qiagen Ltd.,
Manchester, UK). Bisulfite conversion of genomic DNA (500 ng) and methylated and unmethylated
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controls was carried out using the EZ DNA methylation kit (Zymo Research, Cambridge, UK) according
to manufacturer’s instructions. PCR primers for the DKK3 promoter region were designed using
MethPrimer software; primer sequences are in the Supplementary Data. The PCR amplification
method was designed for bisulfite-modified DNA using Touch-Up gradient PCR [65]. A 10-cycle loop,
consisting of 95 ◦C for 30 s, 48 ◦C for 30 s (−0.5 ◦C every cycle), and 72 ◦C for 1 min, was carried
out and repeated five times (50 cycles). CoBRA amplified products were digested with BstUI (Life
Technologies Limited) using 10 µL PCR product (0.1–0.5 µg of DNA) in a final volume of 25 µL with
distilled water for 6 h at 37 ◦C.
4.7. Protein Extraction, Western Blotting, and ELISAs
Two days after cell transfection, media were changed to normal growth medium for cell extracts
or serum-free medium for collection of cell-conditioned media (CM), supplemented with 1 µg/mL
puromycin. Three days later, CM was collected from the cells cultured in serum-free media, and
cells cultured in normal growth medium were washed with cold PBS and lysed in 300 µl RIPA
(0.5% Na deoxycholate, 1% Triton X-100, 20 mM Tris pH 8.0, 0.1% SDS, 150 mM NaCl), with 1 mM
EDTA, cOmpleteTM EDTA-free Protease Inhibitor Cocktail (Sigma-Aldrich Company Ltd.) and 1×
PhosSTOPTM Phosphatase Inhibitor Cocktail (Sigma-Aldrich Company Ltd.). Cells were then collected
by scraping, transferred into a cold centrifuge tube and incubated on ice for 15 min. Lysates were
centrifuged at 4 ◦C (15,000× g) for 15 min and the supernatant collected. Samples were separated
by 6–8% SDS-PAGE and transferred to nitrocellulose or PVDF membranes (Bio-Rad Laboratories
Ltd., Watford, UK). Membranes were blocked in 5% milk powder (Sigma) or 5% BSA (Sigma) in 1×
Tris buffered saline, 0.1% Tween (TBST) for 1 h at room temperature. Blots were probed overnight
with goat anti-DKK3 (1:500) at 4 ◦C. Membranes washed again 3 × 10 min in TBST and incubated
with secondary antibodies (1:5000) for 1 h at room temperature, washed 3 × 5 min in TBST and then
exposed to ECL Clarity reagent (BioRad), exposed to X-ray film, which were developed using an
OptiMax film processor. Membranes were also probed with anti-human GAPDH (1:5,000) for 1 h
at room temperature, and donkey anti-mouse-HRP linked secondary antibody (1:15,000) for 45 min.
ELISAs were performed for CM from transfected cells using the Human Dkk-3 DuoSet kit (R&D
Systems Ltd., Abingdon, UK), according to the manufacturer’s instructions. The absorbance of each
standard and sample was determined using an OptiMax tunable microplate reader (Molecular Devices,
San Jose, CA, USA) set to 450 nm and 540 nm. Samples were quantified based on a standard curve
generated using recombinant purified Dkk-3 (R&D Systems) and a four-parameter logistic curve-fit.
4.8. Gene Reporter, Proliferation, and Migration Assays
Gene reporter assays were carried out using pGL3-CAGA12-luc and pRL-TK as previously
described [24]. Briefly, 200,000 cells/well were plated in triplicate for each treatment in 12-well plates
and transfected on the following day with gRNA, dCas9-VPR, 100 ng pRL-TK, and 400 ng CAGA-luc
per well. After 5 h, an equal volume of medium containing 20% FCS and P/S was added. After 24 h,
cells were treated with TGF-β1 (2 ng/mL) or the same volume of PBS. Cells were incubated for 24 h
and then washed in cold PBS and lysed in 250 µL 1× passive lysis buffer (Promega UK, Southampton,
UK), frozen and thawed, centrifuged at 15,000 rpm for 5 min and subjected to luciferase assays using
the Dual-Glo® luciferase assay kit (Promega), according to manufacturer’s instructions, using a Vector
Light 1420 luminometer. For proliferation assays, cells were plated in triplicate for each time point
(2 days: 200,000 cells/well; 5 days: 50,000 cells/well) in 12-well plates in complete RPMI medium.
On the next morning, cells were transfected with gRNAs and dCas9-VPR as above. After 2 d or 5 d,
cells were washed in PBS, fixed in ice-cold methanol (1 mL/well) for 20 min and allowed to dry for
30 min. Subsequent staining was performed using 0.2% crystal violet in 20% methanol (1 mL/well) for
20 min. A volume of 0.3 mL 10% acetic acid was added to the wells to elute the dye and 100 µL of the
suspension was transferred to a 96-well plate. Optical density (OD) was measured in a plate reader at
(Molecular Devices) at 595 nm. For migration assays, cells were plated in a 6-well plate at a density
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of 200,000 cells/well for the short time-point (2 d) or 50,000 cells/well for the long time-point (5 d).
The day after plating, cells were transfected as above. For the short time point, cells were trypsinized
after 24 h, while for the long time-point this was after 4 d. Cells were centrifuged at 500× g for 5 min
and resuspended in 2 mL serum-free RPMI medium ± 2 ng/mL TGF-β1. 50,000 cells were plated on
8 µm pore Falcon Transwell® polycarbonate membrane inserts (Scientific Laboratory Supplies Ltd.,
Nottingham, UK) in a 24-well plate, in duplicate for each treatment and transfection condition. 800 µL
of complete medium was added to the outside of each insert. Cells were allowed to migrate for 24 h at
37 ◦C, and those that had not migrated were removed with a cotton bud. The inserts were washed
in PBS and cells fixed in cold methanol (1 mL/insert) for 20 min, allowed to dry for 30 min and then
stained with 0.2% crystal violet in 20% methanol (600 µL/insert) for 30 min. Inserts were washed in
distilled water and seven pictures were taken for each insert at 200× magnification using a Nikon
Eclipse TE200-U and QCapture software (Qimaging Inc., Surrey, BC, Canada). Migrated cells were
counted using Image J and the average numbers of migrated cells calculated for each insert. This value
was normalized by dividing the number of migrated cells by the OD reading at 595 nm from additional
wells of cells that had been plated in parallel without inserts to control for effects on cell number.
4.9. Bioinformatics Analysis
MSKCC mRNA expression data were extracted from cBIO (www.cbioportal.org/) for selected
genes using z-score vs normal with threshold ± 2. Oncomine (www.oncomine.org/) was also used to
compare mRNA expression in prostate cancer datasets to determine the extent of their downregulation
across multiple prostate cancer datasets. The differential expression of each gene between PCa and
normal samples was analyzed for fold-change and statistical significance. ToppGene (www.toppgene.
cchmc.org/) was used to investigate the relevance of the genes to the TGF-β signaling pathway, based
on the functional similarity between the seed list and training gene list.
4.10. Statistical Analysis
All data are presented as mean and standard error of mean (SEM) or standard deviation
(SD). Microsoft Excel was used to perform the two sample, paired Student’s t-test to calculate the
statistical significance and to perform one-way ANOVA to compare multiple experimental conditions.
A p-value < 0.05 was considered to be statistical significant. * p < 0.05. For qPCR analysis, ∆∆Ct values
were log-transformed before the test.
5. Conclusions
In conclusion, in this study, we demonstrate that CRISPR-mediated activation of DKK3 expression
is feasible, providing further evidence for potential therapeutic application of this technology, and have
generated results strengthening the link between Dkk-3 and TGF-β regulation of gene expression.
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